Dear Nadia, When you are loosing weight on a low carb diet, does this artificially inflate my pre-diabetes glucose test? Paula Corin Linnwood WA Dear Paula, Pre-diabetes statistics have been in the news for several years with great concern for our national population. It is great that you are staying on top of your health … Continue reading AskNadia: Is My Low Carb Diet Causing a False Pre Diabetes Diagnosis
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system. The drug, now under development by Novo Nordisk, is semaglutide, a GLP-1 (glucagon-like peptide) receptor agonist that the company is hoping to introduce as a … Continue reading Weekly Type 2 Drug to Be Delivered Via Needle Patch
Stress-Induced Hormone Imbalances Go Far Beyond Insulin in Diabetes virtually anything from the stress of a long checkout line to the first signs of menopause can trigger hormone imbalances, which reveal themselves through mood swings, fatigue, migraines, memory problems, and a lackluster sex drive. Imbalances of the hormone insulin–produced by the pancreas to control blood … Continue reading Stress-Induced Hormone Imbalances Go Far Beyond Insulin in Diabetes
We’ve all heard a lot of discussion about low carbohydrate diets and whether they are effective for weight loss and blood sugar control.. What most of us do not understand, however, is how diabetes affects the way that we process carbs. Beta cells make more than insulin: they also make another satiety hormone: amylin. If … Continue reading Why Do We Crave Carbohydrates?
Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma. Dear Diabetes Health: I am asthmatic and was diagnosed with … Continue reading Am I Doing the Right Thing?
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year. The drug is … Continue reading FDA Gives Long-Awaited Nod to Amylin’s Bydureon